Concluding our search for potential dual G9a inhibitors/H3R antagonists for the treatment of PWS in future, significant prerequisites for applying the preclinical candidate A-366 in PWS studies could be identified. This evidence concerns the gene EHMT2 and Prader-Willi syndrome.